Aptevo Therapeutics Inc. Stockholders Equity

Quick Answer

Aptevo Therapeutics Inc. reported Stockholders Equity of $17.38 million for fiscal year 2025.

Aptevo Therapeutics Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $17.38M +265.5%
2024 $4.75M -61.1%
2023 $12.22M -32.0%
2022 $17.97M +1378.1%
2021 $1.22M -92.7%
2020 $16.59M +40.1%
2019 $11.84M -61.1%
2018 $30.41M -62.9%
2017 $82.03M +62.2%
2016 $50.57M -48.0%
2016 $97.20M +8.2%
2016 $89.86M +1.4%
2015 $88.62M -6.3%
2014 $94.61M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $17.39M +293.5% +166.6%
June 30, 2025 $6.52M +46.2% +542.9%
March 31, 2025 -$1.47M -124.1% -131.0%
December 31, 2024 $4.75M -61.1% +7.6%
September 30, 2024 $4.42M -70.0% -1.0%
June 30, 2024 $4.46M -72.5% -26.9%
March 31, 2024 $6.10M -73.8% -50.1%
December 31, 2023 $12.22M -32.0% -17.0%
  • Aptevo Therapeutics Inc. showed an increase of +265.5% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2014–2025 period, Aptevo Therapeutics Inc.’s stockholders equity has declined by 81.6% (from $94.61 million to $17.38 million).
  • The most recent figure is from Aptevo Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment